Neurocrine Biosciences, Inc. (NBIX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Seeking Alpha
Kyle Gano - CEO & Director Todd Tushla - Vice President of Investor Relations Jude Onyia - Chief Scientific Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Presentation Philip Nadeau TD Cowen, Research Division Good morning and welcome once again to TD Cowen's 46th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to moderate a fireside chat with Neurocrine Biosciences. Those of you who follow our research know that Neurocrine is one of our top picks for this year based on its growth prospects. So we're happy to push the team on that today. We have with us Kyle Gano, CEO; Jude Onyia, the CSO; and Todd Tushla, Vice President of IR. Guys, I'll kick it to you to start. Question-and-Answer Session Philip Nadeau TD Cowen, Research Division Can you give us a brief state of the company overview, biggest strengths, biggest challenges? And what does Neurocrine need to achieve
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NBIX) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in MarchPR Newswire
- Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $160.00 price target on the stock.MarketBeat
- Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 2/23/26 - Form 4
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- NBIX's page on the SEC website